Delivery of gene-therapy for heart disease boosted 100-fold; now in 100-patient trial
Researchers developed a method to induce transient ischemia during non-surgical interventional cardiac procedures, boosting adenovector gene transfection by over 100 fold. Cardium Therapeutics' Generx product candidate is being tested in a 100-patient Phase 3 trial for patients with myocardial ischemia and stable angina.